ORIC Logo_RGB.png
ORIC Pharmaceuticals Presents Posters on Four Programs at the 2021 American Association for Cancer Research (AACR) Annual Meeting
April 12, 2021 06:30 ET | ORIC Pharmaceuticals
SOUTH SAN FRANCISCO and SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address...
ORIC Logo_RGB.png
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Update
March 23, 2021 16:05 ET | ORIC Pharmaceuticals
Lead program ORIC-101 on track for two initial data readouts in 2021 Three IND/CTA filings for ORIC-533, -944, and -114 expected in 2021 Cash, Cash Equivalents and Investments of $293.6 million...
ORIC Logo_RGB.png
ORIC Pharmaceuticals to Present Posters on Four Programs at the 2021 American Association for Cancer Research (AACR) Annual Meeting
March 10, 2021 16:30 ET | ORIC Pharmaceuticals
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 10, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that...
ORIC Logo_RGB.png
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
March 02, 2021 06:30 ET | ORIC Pharmaceuticals
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 02, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that...
ORIC Logo_RGB.png
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
February 03, 2021 16:30 ET | ORIC Pharmaceuticals
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb. 03, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that...
ORIC Logo_RGB.png
ORIC Pharmaceuticals Provides Corporate Update and Highlights Key 2021 Milestones
January 11, 2021 06:30 ET | ORIC Pharmaceuticals
Lead program ORIC-101 continues patient enrollment investigating two therapeutic mechanisms of action and on track for two initial data readouts in 2021 Three IND/CTA filings for ORIC-533, -944,...
ORIC Logo_RGB.png
ORIC Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference
January 04, 2021 06:30 ET | ORIC Pharmaceuticals
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 04, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that...
ORIC Logo_RGB.png
ORIC Pharmaceuticals Announces Initiation of Expansion Cohorts in Phase 1b Study of ORIC-101
December 21, 2020 06:30 ET | ORIC Pharmaceuticals
Initiated Part II expansion of the Phase 1b study of ORIC-101 in combination with Abraxane (nab-paclitaxel) using recommended Phase 2 dose selected from Part I of the study Expansion cohorts will...
ORIC Logo_RGB.png
ORIC Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
November 17, 2020 16:15 ET | ORIC Pharmaceuticals
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 17, 2020 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that...
ORIC Logo_RGB.png
ORIC Pharmaceuticals Announces Pricing of Upsized Public Offering
November 13, 2020 06:32 ET | ORIC Pharmaceuticals
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 13, 2020 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that...